China Biotech Services Holdings Limited
Symbol: 8037.HK
HKSE
0.305
HKDTrhová cena dnes
-2.3428
Pomer P/E
0.0000
Pomer PEG
293.79M
MRK Cap
- 0.03%
Výnos DIV
China Biotech Services Holdings Limited (8037-HK) Finančné výkazy
Súvaha
common:word.in-mln USD Growth | TTM | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | 2005 | |||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
balance-sheet.row.cash-and-short-term-investments | 0 | 206.9 | 92.8 | 152.3 | ||||||||||||||||||
balance-sheet.row.short-term-investments | 0 | 0 | -128.6 | 1.8 | ||||||||||||||||||
balance-sheet.row.net-receivables | 0 | 39.2 | 768.5 | 117.6 | ||||||||||||||||||
balance-sheet.row.inventory | 0 | 9.3 | 18.7 | 4.7 | ||||||||||||||||||
balance-sheet.row.other-current-assets | 0 | 5.8 | 4.8 | 3.1 | ||||||||||||||||||
balance-sheet.row.total-current-assets | 0 | 261.2 | 884.8 | 277.8 | ||||||||||||||||||
balance-sheet.row.property-plant-equipment-net | 0 | 124.2 | 128.9 | 105.5 | ||||||||||||||||||
balance-sheet.row.goodwill | 0 | 107.2 | 110.1 | 120.6 | ||||||||||||||||||
balance-sheet.row.intangible-assets | 0 | 69.8 | 67.3 | 80.9 | ||||||||||||||||||
balance-sheet.row.goodwill-and-intangible-assets | 0 | 177 | 177.4 | 201.5 | ||||||||||||||||||
balance-sheet.row.long-term-investments | 0 | 56.9 | 227.7 | 120.3 | ||||||||||||||||||
balance-sheet.row.tax-assets | 0 | 57.6 | -227.7 | 0 | ||||||||||||||||||
balance-sheet.row.other-non-current-assets | 0 | -14.6 | 279.5 | 1.8 | ||||||||||||||||||
balance-sheet.row.total-non-current-assets | 0 | 401.2 | 585.7 | 429 | ||||||||||||||||||
balance-sheet.row.other-assets | 0 | 0 | 0 | 0 | ||||||||||||||||||
balance-sheet.row.total-assets | 0 | 662.4 | 1470.5 | 706.8 | ||||||||||||||||||
balance-sheet.row.account-payables | 0 | 5.8 | 206.4 | 16.1 | ||||||||||||||||||
balance-sheet.row.short-term-debt | 0 | 94.7 | 16.6 | 63.6 | ||||||||||||||||||
balance-sheet.row.tax-payables | 0 | 3.7 | 242 | 85.2 | ||||||||||||||||||
balance-sheet.row.long-term-debt-total | 0 | 5.7 | 65.2 | 3.6 | ||||||||||||||||||
Deferred Revenue Non Current | 0 | -5.7 | 0 | -9.9 | ||||||||||||||||||
balance-sheet.row.deferred-tax-liabilities-non-current | 0 | - | - | - | ||||||||||||||||||
balance-sheet.row.other-current-liab | 0 | 58.6 | 325.2 | 23.7 | ||||||||||||||||||
balance-sheet.row.total-non-current-liabilities | 0 | 12.2 | 95.3 | 13.5 | ||||||||||||||||||
balance-sheet.row.other-liabilities | 0 | 0 | 0 | 0 | ||||||||||||||||||
balance-sheet.row.capital-lease-obligations | 0 | 5.7 | 20.3 | 11.1 | ||||||||||||||||||
balance-sheet.row.total-liab | 0 | 171.6 | 644 | 240.9 | ||||||||||||||||||
balance-sheet.row.preferred-stock | 0 | 0 | 0 | 0 | ||||||||||||||||||
balance-sheet.row.common-stock | 0 | 96.3 | 96.3 | 96.3 | ||||||||||||||||||
balance-sheet.row.retained-earnings | 0 | -310.8 | -209.9 | -475.1 | ||||||||||||||||||
balance-sheet.row.accumulated-other-comprehensive-income-loss | 0 | 186.5 | 225.6 | 283.5 | ||||||||||||||||||
balance-sheet.row.other-total-stockholders-equity | 0 | 490.7 | 490.7 | 490.7 | ||||||||||||||||||
balance-sheet.row.total-stockholders-equity | 0 | 462.8 | 602.7 | 395.4 | ||||||||||||||||||
balance-sheet.row.total-liabilities-and-stockholders-equity | 0 | 662.4 | 1470.5 | 706.8 | ||||||||||||||||||
balance-sheet.row.minority-interest | 0 | 28 | 223.8 | 70.5 | ||||||||||||||||||
balance-sheet.row.total-equity | 0 | 490.7 | 826.5 | 465.9 | ||||||||||||||||||
balance-sheet.row.total-liabilities-and-total-equity | 0 | - | - | - | ||||||||||||||||||
Total Investments | 0 | 56.9 | 99.2 | 122 | ||||||||||||||||||
balance-sheet.row.total-debt | 0 | 100.4 | 81.8 | 67.2 | ||||||||||||||||||
balance-sheet.row.net-debt | 0 | -106.5 | -11 | -83.4 |
Výkaz peňažných tokov
common:word.in-mln USD Growth | TTM | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | 2005 | |||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
cash-flows.row.net-income | 0 | -95.4 | 862.8 | 180.7 | ||||||||||||||||||
cash-flows.row.depreciation-and-amortization | 0 | 55.6 | 66.4 | 68.1 | ||||||||||||||||||
cash-flows.row.deferred-income-tax | 0 | 381.7 | 0 | 7.8 | ||||||||||||||||||
cash-flows.row.stock-based-compensation | 0 | 1.9 | 2 | 5.2 | ||||||||||||||||||
cash-flows.row.change-in-working-capital | 0 | 494.8 | -433.3 | -225.5 | ||||||||||||||||||
cash-flows.row.account-receivables | 0 | 729.9 | -656.4 | -64.9 | ||||||||||||||||||
cash-flows.row.inventory | 0 | -2.2 | -14 | -2.4 | ||||||||||||||||||
cash-flows.row.account-payables | 0 | -232.9 | 237.1 | -158.3 | ||||||||||||||||||
cash-flows.row.other-working-capital | 0 | 0 | 0 | 0 | ||||||||||||||||||
cash-flows.row.other-non-cash-items | 0 | -645.9 | -15.2 | 4.2 | ||||||||||||||||||
cash-flows.row.net-cash-provided-by-operating-activities | 0 | 0 | 0 | 0 | ||||||||||||||||||
cash-flows.row.investments-in-property-plant-an-equipment | 0 | -62.9 | -69.8 | -12.2 | ||||||||||||||||||
cash-flows.row.acquisitions-net | 0 | 7.5 | -6.5 | 0.5 | ||||||||||||||||||
cash-flows.row.purchases-of-investments | 0 | 0 | -51.8 | -0.5 | ||||||||||||||||||
cash-flows.row.sales-maturities-of-investments | 0 | 0 | 0.1 | 4.1 | ||||||||||||||||||
cash-flows.row.other-investing-activites | 0 | 0 | -128.4 | 0 | ||||||||||||||||||
cash-flows.row.net-cash-used-for-investing-activites | 0 | -55.4 | -256.3 | -8.1 | ||||||||||||||||||
cash-flows.row.debt-repayment | 0 | -31.1 | -8.2 | -52.2 | ||||||||||||||||||
cash-flows.row.common-stock-issued | 0 | 0 | 0 | 0 | ||||||||||||||||||
cash-flows.row.common-stock-repurchased | 0 | -3.6 | -3 | -4.3 | ||||||||||||||||||
cash-flows.row.dividends-paid | 0 | -9.6 | 0 | 0 | ||||||||||||||||||
cash-flows.row.other-financing-activites | 0 | -156 | -270.8 | -210.1 | ||||||||||||||||||
cash-flows.row.net-cash-used-provided-by-financing-activities | 0 | -149.4 | -282 | -266.6 | ||||||||||||||||||
cash-flows.row.effect-of-forex-changes-on-cash | 0 | -2.2 | -2.3 | 0.2 | ||||||||||||||||||
cash-flows.row.net-change-in-cash | 0 | 114.1 | -57.8 | -234 | ||||||||||||||||||
cash-flows.row.cash-at-end-of-period | 0 | 206.9 | 92.8 | 150.6 | ||||||||||||||||||
cash-flows.row.cash-at-beginning-of-period | 0 | 92.8 | 150.6 | 384.5 | ||||||||||||||||||
cash-flows.row.operating-cash-flow | 0 | 192.6 | 482.7 | 40.5 | ||||||||||||||||||
cash-flows.row.capital-expenditure | 0 | -62.9 | -69.8 | -12.2 | ||||||||||||||||||
cash-flows.row.free-cash-flow | 0 | 129.7 | 413 | 28.3 |
Riadok výkazu ziskov a strát
common:word.in-mln USD Growth | TTM | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | 2005 | |||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
income-statement-row.row.total-revenue | 0 | 212 | 1851.5 | 623.8 | ||||||||||||||||||
income-statement-row.row.cost-of-revenue | 0 | 177.7 | 750.6 | 265.7 | ||||||||||||||||||
income-statement-row.row.gross-profit | 0 | 34.3 | 1101 | 358 | ||||||||||||||||||
income-statement-row.row.gross-profit-ratio | 0 | 0 | 0 | 0 | ||||||||||||||||||
income-statement-row.row.research-development | 0 | - | - | - | ||||||||||||||||||
income-statement-row.row.selling-general-administrative | 0 | - | - | - | ||||||||||||||||||
income-statement-row.row.selling-and-marketing-expenses | 0 | - | - | - | ||||||||||||||||||
income-statement-row.row.other-expenses | 0 | 0.6 | -3.4 | 0.7 | ||||||||||||||||||
income-statement-row.row.operating-expenses | 0 | 158 | 251.5 | 168.8 | ||||||||||||||||||
income-statement-row.row.cost-and-expenses | 0 | 335.7 | 1002.1 | 434.5 | ||||||||||||||||||
income-statement-row.row.interest-income | 0 | 3.7 | 0.2 | 0 | ||||||||||||||||||
income-statement-row.row.interest-expense | 0 | 5.3 | 3.5 | 6.5 | ||||||||||||||||||
income-statement-row.row.selling-and-marketing-expenses | 0 | - | - | - | ||||||||||||||||||
income-statement-row.row.total-other-income-expensenet | 0 | -10.7 | 11.1 | -8.8 | ||||||||||||||||||
income-statement-row.row.ebitda-ratio-caps | 0 | - | - | - | ||||||||||||||||||
income-statement-row.row.other-operating-expenses | 0 | 0.6 | -3.4 | 0.7 | ||||||||||||||||||
income-statement-row.row.total-operating-expenses | 0 | -10.7 | 11.1 | -8.8 | ||||||||||||||||||
income-statement-row.row.interest-expense | 0 | 5.3 | 3.5 | 6.5 | ||||||||||||||||||
income-statement-row.row.depreciation-and-amortization | 0 | 55.6 | 58.4 | 68.1 | ||||||||||||||||||
income-statement-row.row.ebitda-caps | 0 | - | - | - | ||||||||||||||||||
income-statement-row.row.operating-income | 0 | -123.7 | 851.7 | 189.4 | ||||||||||||||||||
income-statement-row.row.income-before-tax | 0 | -134.3 | 862.8 | 180.7 | ||||||||||||||||||
income-statement-row.row.income-tax-expense | 0 | -1.3 | 157.3 | 48.1 | ||||||||||||||||||
income-statement-row.row.net-income | 0 | -95.4 | 705.6 | 132.6 |
Často kladené otázky
Čo je China Biotech Services Holdings Limited (8037.HK) celkové aktíva?
China Biotech Services Holdings Limited (8037.HK) celkové aktíva sú 662362000.000.
Aký je ročný obrat podniku?
Ročné príjmy sú N/A.
Aké je ziskové rozpätie podniku?
Zisková marža firmy je 0.100.
Aký je voľný peňažný tok podniku?
Voľný peňažný tok je 0.200.
Aká je čistá zisková marža podniku?
Čistá zisková marža je -0.535.
Aké sú celkové výnosy podniku?
Celkové príjmy sú -0.796.
Aká je China Biotech Services Holdings Limited (8037.HK) čistý zisk (čistý príjem)?
Čistý zisk (čistý príjem) je -95447000.000.
Aký je celkový dlh firmy?
Celkový dlh je 100396000.000.
Aké je číslo prevádzkových nákladov?
Prevádzkové výdavky sú 158009000.000.
Aký je údaj o hotovosti spoločnosti?
Peňažné prostriedky podniku sú 0.000.